Toruniak

Researchers are evaluating a personalized prevention program (PPP) for people with stable coronary heart disease (CHD) who are at high risk for cardiovascular (CV) events. This prospective clinical study has two parts: Part A involves screening 12,000 CHD patients to validate biomarkers that predict CV events and identify those at highest risk. Part B is a randomized clinical trial with 2,000 high-risk patients comparing the PPP to usual care (UC) to assess the program's clinical value and cost-effectiveness. In the PPP group, participants will attend six visits over three years to receive lifestyle coaching and exercise prescriptions guided by trained staff and supervised by investigators. These sessions are supported by digital tools called the CoroPrevention Tool Suite. The study also monitors medication use and adherence through these visits. The usual care group will receive standard treatment without the personalized program. Throughout the study, participants will undergo biomarker testing, responses to questionnaires on nutrition and exercise, and assessments of heart health outcomes such as CV death, heart attacks, or heart failure events. Researchers will also evaluate behavioral changes, exercise adherence, medication use, and user experiences with the digital tools. The study includes follow-ups at multiple time points, lasting three years to measure the impact of the personalized prevention program compared to usual care.